Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

CMMB
Chemomab Therapeutics Ltd.
stock NASDAQ ADR

At Close
Sep 16, 2026 3:59:30 PM EDT
2.64USD+6.883%(+0.17)115,071
0.00Bid   0.00Ask   0.00Spread
Pre-market
Sep 16, 2026 9:27:30 AM EDT
2.52USD+2.024%(+0.05)3,695
After-hours
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 20, 2022
06:11AM EST  Adi Mor Reported 11.5% Stake in Chemomab Therapeutics in 13D Filing   Benzinga
Jan 4, 2022
07:01AM EST  Chemomab Therapeutics Names Jack Lawler Vice President of Global Clinical   PR Newswire
Dec 20, 2021
08:02AM EST  Chemomab to Participate in LifeSci Partners Annual Corporate Access Event and   PR Newswire
Dec 16, 2021
04:10PM EST  Chemomab Therapeutics Announces Expected Appointment Of Dale R. Pfost As Chairman Of The Board   Benzinga
04:06PM EST  Chemomab Therapeutics Announces Expected Appointment of Dale R. Pfost as   PR Newswire
Dec 7, 2021
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021   Benzinga
09:08AM EST  Aegis Capital Initiates Coverage On Chemomab Therapeutics with Buy Rating, Announces Price Target of $30   Benzinga
Dec 3, 2021
08:05AM EST  Chemomab Therapeutics Names David M. Weiner, MD As Interim Chief Medical Officer   Benzinga
Dec 2, 2021
07:51AM EST  The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance   Benzinga
07:08AM EST  Chemomab Announced FDA Clearance of Its IND Application for CM-101, a First-In-Class CCL24 Neutralizing Antibody for the Treatment of Primary Sclerosing Cholangitis   Benzinga
Nov 12, 2021
07:22AM EST  Chemomab Therapeutics Q3 EPS $0.013 vs $0.009 In Same Qtr. Last Year   Benzinga
07:07AM EST  Amended: Chemomab Therapeutics Q3 Net Loss $2.97 Mln Vs Net Loss $1.22 Mln Last Year   RTTNews
07:06AM EST  Chemomab Therapeutics Q3 Net Loss $2.97 Mln Vs Net Income $1.22 Mln Last Year   RTTNews
07:01AM EST  Chemomab Therapeutics Announces Third Quarter 2021 Financial Results and   PR Newswire
Nov 10, 2021
07:01AM EST  Chemomab Announces Poster Presentation at AASLD's The Liver Meeting(r) 2021   PR Newswire
Nov 9, 2021
07:01AM EST  Chemomab to Present at Stifel 2021 Virtual Healthcare Conference   PR Newswire
Nov 8, 2021
08:14AM EST  Chemomab Therapeutics Ltd. (CMMB), a company focused on the innovative therapeutics for fibrotic and inflammatory diseases, on Monday said it has appointed Donald Marvin as Chief Financial Officer, Executive Vice President, and Chief Operating Officer. Marvin is succeeding interim CFO Sigal Fattal, who will be serving as senior financial advisor to the newly appointed CFO.   RTTNews
07:23AM EST  Chemomab Therapeutics Appoints Donald R. Marvin Chief Financial Officer, Executive Vice President and Chief Operating Officer   Benzinga
07:16AM EST  Chemomab Therapeutics Names Donald Marvin CFO, EVP And COO   RTTNews
07:02AM EST  Chemomab Therapeutics Names Donald R. Marvin Chief Financial Officer, Executive   PR Newswire
Oct 26, 2021
08:54AM EDT  Chemomab Therapeutics Hosting Key Opinion Leader Webinar on Systemic Sclerosis   PR Newswire
Oct 21, 2021
06:17AM EDT  The following are some of the stocks making big moves in Thursday's pre-market trading (as of 06.05 A.M. EDT).   RTTNews
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Oct 1, 2021
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 30, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug   Benzinga
Sep 27, 2021
07:21AM EDT  Chemomab Therapeutics Collaborates With Leeds University To Further Study The Role Of CCL24   RTTNews
07:12AM EDT  Chemomab Therapeutics Collaborate with Leeds University to Elucidate Role of CCL24   Benzinga
07:01AM EDT  Elucidate the Role of CCL24 in Vascular Damage Associated with Systemic Sclerosis   PR Newswire
Sep 2, 2021
07:31AM EDT  Chemomab Therapeutics Ltd. (CMMB), an Israeli clinical-stage biotech company, announced Thursday that it has appointed Dale Pfost as Chief Executive Officer. Pfost is expected to join the Board of Directors and subsequently become the company's Chairman in 2022.   RTTNews
07:16AM EDT  Chemomab Therapeutics Announces Appointment Of Dale Pfost As Chief Executive Officer   Benzinga
07:02AM EDT  Chemomab Therapeutics Appoints Dale Pfost As CEO   RTTNews
07:01AM EDT  Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive   PR Newswire
Sep 1, 2021
07:19AM EDT  Chemomab to Participate in Upcoming September Investor Conferences   PR Newswire
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 13, 2021
08:07AM EDT  Chemomab Therapeutics Q2 Loss $2.8 Mln Or $0.01/shr Vs. Loss $1.1 Mln Or $0.01/shr Prior Year   RTTNews
08:04AM EDT  Chemomab Therapeutics Q2 EPS $(0.01), Same YoY   Benzinga
08:01AM EDT  Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and   PR Newswire
Jun 23, 2021
08:35AM EDT  Chemomab Therapeutics, AGC Biologics Expand Partnership To Manufacture CM-101 To Support Phase II/III Clinical Testing   RTTNews
08:35AM EDT  Chemomab Therapeutics, AGC Biologics Expand Partnership To Manufacture CM-101 For Phase II/III   Benzinga
08:32AM EDT  Chemomab Therapeutics reports Expanded Partnership With AGC Biologics To Manufacture CM-101 For Phase 2/3   Benzinga
08:31AM EDT  Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture   PR Newswire
08:30AM EDT  Chemomab Therapeutics and AGC Biologics Expand Partnership to   GlobeNewswire Inc
Jun 10, 2021
07:01AM EDT  Chemomab Announces Poster Presentation at the International Liver Congress 2021   PR Newswire
May 26, 2021
10:09AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2021   Benzinga
07:27AM EDT  Cantor Fitzgerald Initiates Coverage On Chemomab Therapeutics with Overweight Rating, Announces Price Target of $45   Benzinga
May 13, 2021
09:26AM EDT  Chemomab Q1 2021 Net Loss Of $17M   Benzinga
09:25AM EDT  Chemomab Therapeutics Announces First Quarter 2021 Financial Results and   PR Newswire
May 12, 2021
07:04AM EDT  Chemomab to Present at Oppenheimer's Virtual Rare And Orphan Disease Summit May 21   Benzinga
07:01AM EDT  Chemomab to Present at Oppenheimer's Virtual Rare and Orphan Disease Summit   PR Newswire
May 7, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 7, 2021   Benzinga
07:00AM EDT  Oppenheimer Initiates Coverage On Chemomab Therapeutics with Outperform Rating, Announces Price Target of $42   Benzinga
Apr 30, 2021
04:05PM EDT  Chemomab Therapeutics Ltd Files For Mixed Shelf Of Up To $200M   Benzinga
Apr 26, 2021
06:35AM EDT  Chemomab Enrolls First Patient In Phase 2a Study Of CM-101 In Non-Alcoholic Steatohepatitis   RTTNews
06:32AM EDT  Chemomab Therapeutics Reports Enrollment Of First Patient In Phase 2a Study Of CM-101 In Non-Alcoholic Steatohepatitis   Benzinga
06:30AM EDT  Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in   PR Newswire
Apr 15, 2021
04:11PM EDT  Chemomab Therapeutics files For Resale Of Up To 7.213M ADSs By Selling Shareholders   Benzinga
Mar 29, 2021
09:01AM EDT  Chemomab Announces Four New Appointments to the Board of Directors and   PR Newswire
Mar 26, 2021
08:11AM EDT  Rivendell Investments Reports In 13G Filing A 10.6% Stake In Chemomab   Benzinga
Mar 22, 2021
07:00AM EDT  Genesis Prize Co-Founder Stan Polovets Steps Down as Chairman of Anchiano   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC